The androgen receptor has no direct antiresorptive actions in mouse osteoclasts by Sinnesael, Mieke et al.
The androgen receptor has no direct antiresorptive actions in
mouse osteoclasts
Mieke Sinnesael a,1, Ferran Jardi a,1, Ludo Deboel a, Michaël R. Laurent b,c, Vanessa Dubois b,
Jeffrey D. Zajac d, Rachel A. Davey d, Geert Carmeliet a, Frank Claessens b,
Dirk Vanderschueren a,*
a Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
b Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
c Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
d Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia
A R T I C L E I N F O
Article history:
Received 13 January 2015
Received in revised form 29 April 2015
Accepted 29 April 2015
Available online
Keywords:
Androgen receptor
Androgens
Bone marrow stromal cell
Bone resorption
Osteoblast
Osteoclast
A B S T R A C T
Androgen deﬁciency or androgen receptor knockout (ARKO) causes high-turnover osteopenia, but the
target cells for this effect remain unclear. To examine whether AR in osteoclasts directly suppresses bone
resorption, we crossed AR-ﬂoxed with cathepsin K-Cre mice. Osteoclast-speciﬁc ARKO (ocl-ARKO) mice
showed no changes neither in osteoclast surface nor in bone microarchitecture nor in the response to
orchidectomy and androgen replacement, indicating that the AR in osteoclasts is not critical for bone
maintenance. In line with the lack of a bone phenotype, the levels of AR were very low in osteoclast-
enriched cultures derived from bone marrow (BM) and undetectable in osteoclasts generated from spleen
precursors. Since tibiae of ubiquitous ARKO mice displayed increased osteoclast counts, the role of AR
was further explored using cell cultures from these animals. Osteoclast generation and activity in vitro
were similar between ARKO and wildtype control (WT) mice. In co-culture experiments, BM stromal cells
(BMSCs) were essential for the suppressive action of AR on osteoclastogenesis and osteoclast activity.
Stimulation with 1,25(OH)2 vitamin D3 increased Rankl and decreased Tnfsf11 (osteoprotegerin, Opg) gene
expression in BMSCs more than in osteoblasts. This increase in the Rankl/Opg ratio following 1,25(OH)2D3
stimulation was lower, not higher, in ARKOmice. Runx2 expression in BMSCs was however higher in ARKO
vs. WT, suggesting that ARKOmice may more readily commit osteoprogenitor cells to osteoblastogenesis.
In conclusion, the AR does not seem to suppress bone resorption through direct actions in osteoclasts.
BMSCs may however represent an alternative AR target in the BM milieu.
© 2015 Published by Elsevier Ireland Ltd.
1. Introduction
Osteoporosis in men is less common than in women but still rep-
resents an important burden for public health (Khosla et al., 2008).
Greater cortical bone expansion during peak bone mass acquisi-
tion is the main reason why the skeleton of men is stronger
compared to women (Seeman, 2003). Androgens such as testos-
terone (T) stimulate periosteal bone formation through the androgen
receptor (AR), whereas estrogens such as 17β-oestradiol (E2) via es-
trogen receptor alpha (ERα) have an inhibitory effect on cortical bone
expansion (Vanderschueren et al., 2014). Because in aging, men
maintain their sex steroid levels better than women, they do not
experience the accelerated phase of bone loss observed after meno-
pause in women. However a slow decline in the levels of bioavailable
androgens and therefore also in E2, since androgens are the sub-
strate for the aromatase enzyme and production of estrogens, could
contribute to osteoporosis in aging men (Laurent et al., 2015). Al-
though non-aromatizable androgens can prevent bone resorption
in rodent models, it remains controversial whether this is also the
case in humans. Several experimental studies (Falahati-Nini et al.,
2000; Idan et al., 2010; Laurent et al., 2015) have demonstrated that
androgens were unable to prevent bone resorption in the face of
estrogen deﬁciency and although theymay selectively inﬂuence bone
formation (Falahati-Nini et al., 2000), this has not been shown to
translate into preservation of bone mass in aging men.
Bone maintenance is determined by osteoclastic bone resorp-
tion and osteoblastic bone formation. Resorption and formation are
coupled processes; indeed, osteoclasts release matrix-embedded
factors and secrete the so-called clastokines which stimulate
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osteoblasts, while osteoblasts and other cells release factors such
as macrophage colony-stimulating factor (M-CSF), receptor activa-
tor of nuclear factor kappa B ligand (RANKL) and osteoprotegerin
(OPG) which modulate osteoclast generation and activity (Sims and
Martin, 2014). In mouse models, androgens via the AR restrain bone
turnover by inhibiting both osteoclastogenesis and osteoblastogenesis
(Bellido et al., 1995; Kawano et al., 2003; Venken et al., 2006).
However, whether osteoblasts, osteocytes, osteoclasts or other cells
constitute the main targets for AR actions in restraining bone turn-
over remains unclear (Manolagas et al., 2013; Vanderschueren et al.,
2014).
Osteoclast generation, activity and lifespan critically depend on
M-CSF and RANKL secretion by osteoblasts, osteocytes and other
cells in the bonemarrow (BM)milieu (Arai et al., 1999; Bellido et al.,
1995; Xiong et al., 2011). Rankl expression has been found
upregulated in osteoblasts of ARKO mice, suggesting that the AR in
osteoblasts is critical for the suppressive effect of androgens on os-
teoclast generation and activity (Kawano et al., 2003). Several animal
studies have suggested that the AR might be expressed in osteo-
clasts and exert effects on these cells in vitro (Huber et al., 2001;
Mizuno et al., 1994; Pederson et al., 1999; van der Eerden et al.,
2002), although it remains controversial whether the AR inhibits
osteoclasts directly. Conditional knockout models have demon-
strated that ERα in osteoclasts mediates bone resorption in female
but not in male mice (Martin-Millan et al., 2010; Nakamura et al.,
2007). Similarly, a recent study in an osteoclast-speciﬁc deletion
model for the AR has shown that the anti-resorptive effects of an-
drogens are not derived from their direct action on these cells (Ucer
et al., 2015). However, these new data contradict the results from
the only previous study until now which had investigated the ab-
lation of AR in osteoclasts in vivo (Nakamura et al., 2004). Therefore,
further studies are required as to clarify the androgenic action in
osteoclasts. Osteoblasts derive from the mesenchymal lineage via
BM stromal cells (BMSCs), which commit to the osteoblast lineage
once RUNX2 is expressed (Komori, 2011). Cre-mediated deletion of
the AR in mature osteoblasts using the Col1a1 (Notini et al., 2007)
or the osteocalcin (Chiang et al., 2009; Määttä et al., 2013) pro-
moter showed respectively no increased osteoclast surface and
increased osteoclast numbers/surface. Recently, we have shown using
Dmp1-Cre mice that loss of AR in mature osteoblasts and osteo-
cytes resulted in similar, moderate trabecular bone loss (Sinnesael
et al., 2012). Although we could not demonstrate increased bone
resorption in this model, the effect on trabecular number and the
lack of difference in anabolic response to a mechanical loading stim-
ulus suggests that also in this model, a slow, age-accumulating
increase in bone resorption is responsible for the observed trabecu-
lar bone losses. These different models suggest a direct role of AR
across the entire osteoblast lineage, although the data do not fully
explain the suppressive effects of androgens on bone resorption (Imai
et al., 2013).
The main goal of this study was to investigate to what extent
the effects of androgens on osteoclasts are direct through the AR.
For this purpose, we generated a speciﬁc knockout model in which
the AR is ablated in mature osteoclasts. In addition, we compared
the generation and activity of osteoclasts in primary cultures from
BM of our global ARKO and wildtype control (WT) mice. Finally, we
co-cultured osteoblasts from ARKO orWTmice with BM from ARKO
or WT in order to explore potential alternative mechanisms ex-
plaining the anti-resorptive effects of the AR.
2. Materials and methods
2.1. Animal care
All transgenicmice had a >95% C57BL/6J genetic background.Mice
were group-housed under conventional conditions: 12-h light/
dark cycle, standard diet (1% calcium, 0.76% phosphate), and water
ad libitum in standard cages. The Animal Ethical Committee of the
KU Leuven approved all procedures (P143/2011).
2.2. Generation of global ARKO and osteoclast-speciﬁc ARKO (ocl-
ARKO) mice
Global ARKO mice have been previously generated by crossing
mice with an ubiquitous Cre to mice with a ﬂoxed second exon of
the AR (De Gendt et al., 2004). Mice with an osteoclast-selective
knockout of the AR (ocl-ARKO) were generated by crossing female
mice heterozygous for a ﬂoxed exon 2 AR allele (AR(ex2)ﬂox+/−) (De
Gendt et al., 2004) with male mice heterozygously carrying a cy-
clization recombinase of which the expression is controlled by the
cathepsin K promoter (Ctsk-Cre, kindly provided by Prof. R. Davey)
(Chiu et al., 2004; Turner et al., 2011). Male offspring were weaned
at 3 weeks of age and genotyped by PCR as described previously
(De Gendt et al., 2004). The presence of the Ctsk-Cre transgene was
determined on genomic DNA via PCR with forward primer: 5′-
GCGGCATGGTGCAAGTTGAAT-3′ and reverse primer: 5′-
ACCCCCAGGCTAAGTGCCTT-3′ resulting in a 534 bp fragment.
2.3. Orchidectomy and replacement
At the age of 12 weeks ocl-ARKO and control (ARﬂ/Y; Ctsk-Cre−/
−) male mice were either sham-operated (sham), orchidectomized
(ORX) or ORX and immediately given a silastic tube with testos-
terone (Serva, Heidelberg, Germany) replacement (ORX+T) using
subcutaneous silastic implants (Silclear Tubing, Degania Silicone,
Jordan Valley, Israel) in the cervical region (Vanderschueren et al.,
2000). After 4 weeks animals were euthanized and eﬃcacy of ORX
and T replacement was veriﬁed by measurement of seminal vesicle
wet weights. Femurs were collected and analyzed with μCT.
2.4. μCT analysis
μCT analysis was done ex vivo on the left femur by using a Skyscan
1172 scanner (Brüker, Kontich, Belgium) as described (Sinnesael et al.,
2012). Cortical bone was analyzed starting at a distance of 2.75mm
from the growth plate and extending 0.5 mm distally (100 slices,
5 μm voxel size) to determine cortical area (Ct.Ar, mm2), cortical
thickness (Ct.Th, mm), periosteal bone perimeter (PsPm, mm),
endocortical bone perimeter (EcPm, mm) andmedullar area (Me.Ar,
mm). The parameters evaluated in the trabecular region of the distal
femur, commencing at a distance of 0.5 mm from the growth plate
and extending a further 1.5 mm proximally, included bone volume/
tissue volume (BV/TV,%), trabecular thickness (Tb.Th, mm), trabecular
number (Tb.N, mm−1) and trabecular separation (Tb.Sp, mm)
(Callewaert et al., 2009).
2.5. Bone histomorphometry
Right tibias and femurs were prepared and stained with tartrate-
resistant acid phosphatase (TRAP) to visualize osteoclasts as
described (Sinnesael et al., 2012). Histomorphometric analysis
was done by using a Zeiss Axiovert microscope and an Axiovision
(v6.1.0) image analysis system (Daci et al., 2000; Masuyama et al.,
2006). Osteoclast surface (Oc.S) was determined as % of bone surface
(BS).
2.6. Primary bone marrow stromal cell and osteoclast-enriched
cultures
In vitro osteoclast generation was assessed ﬁrst by culturing BM-
derived hematopoietic cells in the presence of exogenous M-CSF
(R&D Systems, Abingdon, UK) and RANKL (Peprotech, Rocky Hill,
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NJ, USA) as described (Daci et al., 2000; Verlinden et al., 2013).
Brieﬂy, BM cells were isolated from the long bones of hindlimbs
of 8–10 week old global ARKO and WT mice and centrifuged
on Ficoll–Paque gradient (Stem Cell Technologies, Grenoble, France)
to isolate mononuclear cells. The BM cells were plated overnight
in α-MEM supplemented with 10% FBS and containing 10 ng/mL
M-CSF.
For osteoclast-enriched cultures, the non-adherent cells were
harvested the next day and plated at 1.5 × 106 cells/well in a 48
well dish in α-MEM supplemented with 10% FBS and containing
M-CSF (20 ng/mL) and RANKL (100 ng/mL). The medium was re-
placed every 3–4 days. After 7 days of culture, TRAP staining was
performed after a 10 min ﬁxation of cells with 4% paraformalde-
hyde and permeabilization for 5min with 0.1% Triton X-100 (Sigma-
Aldrich). Cells were subsequently incubated at room temperature
in 0.1 M sodium acetate containing naphtol AS-MX phosphate and
Fast Red violet LB salt (Sigma-Aldrich, Bornem, Belgium), in the
presence of 1% dimethylformamide (Merck, Darmstadt, Germany).
Cells stained positively and containing 3 or more nuclei were con-
sidered osteoclasts and counted on digital images with ImageJ
software.
For BMSC cultures, the adherent cells were plated in a 6 well dish
at 1.5 × 106 cells/mL in α-MEMmedium supplemented with 10% FBS
in the presence or absence of 10−8 M 1,25-dihydroxyvitamin D3
(1,25(OH)2D3) (Sigma-Aldrich). Medium was replaced every 3 days.
After 14 days of culture, the cells were used for RNA isolation.
2.7. Generation of osteoclasts from spleen precursors
Mature osteoclasts of WT and global ARKO mice were also ob-
tained from spleen precursors by utilizing soluble forms of M-CSF
and RANKL (Bradley and Oursle, 2008). Brieﬂy, after centrifuging
on Ficoll–Paque, spleen cells were cultured at 106 cells/mL in α-MEM
supplemented with 10% FBS and containing M-CSF (20 ng/mL) and
RANKL (100 ng/mL). The mediumwas replaced every 3–4 days. RNA
from differentiated osteoclasts was extracted on day 7.
2.8. Co-culture of calvarial osteoblasts and hematopoietic
precursor cells
Osteoblasts were isolated from calvariae of neonatal WT and
global ARKO mice. Calvariae were sequentially digested with 0.1%
collagenase A and 0.2% dispase (Sigma-Aldrich) as described pre-
viously (Daci et al., 2000). Cells released during digestion cycles 2–6
were pooled and used in experiments. BM cells were collected from
the femurs of 8–10 week old control and global ARKO mice as de-
scribed earlier. TRAP-positive multinucleated osteoclasts were
generated by co-culturing calvarial osteoblasts (2 × 104 cells/well in
a 48-well dish) and BM cells (2 × 105 cells/well in a 48-well) in
α-MEM medium supplemented with 10% FBS and in the presence
of 10−8 M 1,25(OH)2D3. For osteoclast quantiﬁcation, the average
number of TRAP-positive cells with more than three nuclei X20 ﬁeld
was obtained at 8 days of culture.
2.9. Matrix dissolution assay
Osteoclasts were formed following the procedure of “Primary os-
teoclast enriched cultures” or “Co-culture of calvarial osteoblasts
and hematopoietic precursor cells” directly on Osteo Assay Surface
wells (Corning, Amsterdam, The Netherlands), which contains a
matrix that osteoclasts can resorb. On day 7 the plate was stained
for TRAP or bleached to visualize the resorbed surface area. The per-
centage of resorbed surface was assessed with ImageJ on digital
images captured with an LSM 510 Axiovert 100Mmicroscope (Carl
Zeiss Ltd, Welwyn Garden City, UK).
2.10. RNA isolation, cDNA synthesis, and Q-PCR
Tissue samples (brain, adipose tissue, heart, liver, quadriceps,
testis) as well as tibia, BM, osteoclast-enriched cells, hematopoi-
etic cells, stromal cells and calvarial osteoblasts were obtained at
12 weeks of age and snap-frozen in liquid nitrogen. cDNA was syn-
thesized from DNaseI-treated total RNA (RNeasy Kit, Qiagen,
Chatsworth, CA, USA) by using superscript II RNaseH− reverse tran-
scriptase and random hexamer primers (Invitrogen, Ghent, Belgium).
The following primers and probes were used for the androgen re-
ceptor (AR): forward primer: 5′-GACATGCGTTTGGACAGTACCA-3′;
reverse primer: 5′-TGACAGCCAGAAGCTTCATCTC-3′; probe: 5′-
CCCAGAAGACCTGCCTGATCTGTG-3′ (amplicon = 82 bp); receptor
activator of nuclear factor kappa-B ligand (RANKL): forward primer:
5′-CATTTGCACACCTCACCATCA-3′; reverse primer: 5′-TTGCTTAA
CGTCATGTTAGAGATCTTG-3′; probe: 5′-TCGGGTTCCCATAAAGTC
ACTCTGTCCTCTT-3′ (amplicon = 118 bp); osteoprotegerin (OPG):
forward primer: 5′-GAAGGGCGTTACCTGGAGATC-3′; reverse primer:
5′-CTGAATTAGCAGGAGGCCAAAT-3′; probe: 5′-TCACCTGAGAAG
AACCCATCTGGACATTTT-3′ (amplicon = 201 bp); runt-related tran-
scription factor 2 (RUNX2): forward primer: 5′-TACCAGCCAC
CGAGACCAA-3′; reverse primer: 5′-AGAGGCTGTTTGACGCCATAG-
3′; probe: 5′-CTTGTGCCCTCTGTTGTAAATACTGCTTGCA-3′
(amplicon = 94 bp). Expression of the main osteoclastogenic
cytokines, namely tumor necrosis factor alpha (TNF-α) and
interleukin 1 and 6 (IL-1α, IL-1β and IL-6), was determined by using
predesigned TaqMan® Assays (TNF-α; Mm00443258_m1, IL-1α;
Mm00439620_m1, IL-1β; Mm00434228_m1 and IL-6;
Mm00446190_m1). For quantiﬁcation of gene expression, the ABI
Prism 7500 sequence detector PCR detection system (Applied
Biosystems, Ghent, Belgium) was used with a two-step RT-
quantitative PCR protocol. The relative expression levels of the target
genes were calculated as a ratio to the hypoxanthine–guanine
phosphoribosyl transferase (HPRT) gene with the following primers:
forward primer: 5′-TTATCAGACTGAAGAGCTACTGTAATGATC-3′;
reverse primer: 5′-TTACCAGTGTCAATTATATCTTCAACAATC-3′; probe:
5′-TGAGAGATCATCTCCACCAATAACTTTTATGTCCC-3′
(amplicon = 127 bp).
2.11. Genomic DNA isolation of osteoclast enriched cells
Genomic DNA was isolated from osteoclast-enriched cells (see
primary osteoclast enriched culture) with Qiagen blood & cell culture
DNA minikit (Qiagen Benelux B.V., KJ Venlo, The Netherlands). The
recombination of the AR gene was detected by PCR, as described
previously (De Gendt et al., 2004).
2.12. Osteocalcin and TRAPCP5b assays
Serum osteocalcin and tartrate-resistance acid phosphatase
(TRACP5b) were measured by an in-house radioimmunoassay (RIA)
(CV intra-assay <5.9%; CV interassay <5.2%) (Verhaeghe et al., 1989)
and by a MouseTRAPTM Enzyme-Linked Immuno Sorbent Assay
(ELISA) kit (ids, Elitech Benelux, Belgium) (CV intra-assay <7%; CV
interassay <8%), respectively.
2.13. Statistical analysis
Statistical analysis was performed using NCSS software (NCSS,
Kaysville, UT, USA). Student’s t test and one-way ANOVA followed
by Fisher’s least signiﬁcant differencesmultiple comparison test were
performed to assess signiﬁcance of differences between two or more
groups. Data are represented as means ± SEM, and a p-value of <0.05
was considered signiﬁcant.
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3. Results
3.1. Generation and characterization of osteoclast-speciﬁc ARKO
(ocl-ARKO) mice
To gain further insights regarding the possible target cell of AR-
mediated androgen action on bone, the AR gene inmature osteoclasts
was disrupted. In an initial experiment the seminal vesicle weight/
body weight, femur length and bone parameters with μCT of 12-
week-old WT (ARWT/Y; Ctsk-Cre−/−), hemizygous ﬂoxed (ARﬂ/Y; Ctsk-
Cre−/−), hemizygous Ctsk-Cre (ARWT/Y; Ctsk-Cre+/−) and ocl-ARKO (ARﬂ/
Y; Ctsk-Cre+/−) were assessed (Supplementary Table S1). Because there
were no differences in the bone parameters between the 3 control
groups, we used ﬂox mice (ARﬂ/Y; Ctsk-Cre−/−) as controls in our
further experiments.
To further characterize this newmouse model, AR expression was
assessed in different tissues. AR mRNA levels in testis, heart, kidney,
brain, fat, liver andquadricepsmusclewerenotdifferent betweencontrol
and ocl-ARKOmice (Fig. 1B). However, as shown in Fig. 1A, AR mRNA
was very low in osteoclast-enriched cells, and decreased during in vitro
differentiation of hematopoietic cells toward osteoclasts. No signiﬁ-
cant differences in AR expression could be demonstrated at themRNA
level (Fig. 1A). Cremediated excisionwas detectedwith PCRongenomic
DNA in ocl-ARKO and not in controls (Fig. 1C), although a large ARﬂox/Y
band (930 bp) was still visible. Ctsk expression was very high in the
osteoclast-enriched cultures, with no signiﬁcant difference between
genotypes (data not shown).
Deletion of theARonosteoclasts hadneither an effect on trabecular/
cortical bone nor on serum bone turnover markers (Table 1), as
determined at 12 and 32weeks of age. In consistence with the lack of
bone phenotype, osteoclast surface (Oc.S/BS) remained unaltered in the
femur of ocl-ARKO mice compared to controls regardless of age, al-
though 32-week-old animals showed higher values (Table 1).
The response in trabecular bone volume following ORX and T
replacement was similar in ocl-ARKO and controls (Fig. 2). Andro-
gen dosage was slightly supraphysiological, since the seminal vesicle
weight corrected for body weight was signiﬁcantly higher in the T
replacement groups compared to sham mice (13.1 mg/g BW ± 0.5
vs. 9.0mg/g ± 0.4). The weight of the seminal vesicles after ORX was
very low (0.2 mg/g BW ± 0.4).
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A
Fig. 1. Generation and validation of ocl-ARKO mice. (A) Quantitative real-time PCR analysis of AR mRNA in osteoclast-enriched, BM-derived hematopoietic and calvarial
osteoblast cell cultures of ARKO, ocl-ARKO and control mice. Values are expressed as the mean of three independent experiments (n = 3 mice/group in each experi-
ment) ± SEM. (B) Quantitative real-time PCR analysis of AR in different tissues of control and ocl-ARKO mice (n = 8–10). (C) PCR analysis of extracted DNA from osteoclast-
enriched cultures derived from ARKO, ocl-ARKO (ARﬂox/YCtsk-Cre+/−) and ﬂox control (ARﬂox/YCtsk-Cre−/−) mice. The 400 bp PCR fragment is detected in ocl-ARKO (circled in
red), indicating Cre-mediated excision. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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3.2. AR gene expression in different bone marrow cell populations
Different cell populations were derived from the BM of ARKO and
corresponding WT mice. For this purpose, tibiae were ﬂushed and
BM-derived cells were plated after Ficoll puriﬁcation. After 24 h in
culture, the non-adherent cells (called here hematopoietic cells) were
cultured in the presence of RANKL andM-CSF to form the osteoclast-
enriched cells. The term “osteoclast-enriched cells” is used since it
cannot be excluded that some stromal cells are still present. To cir-
cumvent this potential stromal contamination, mature osteoclasts
were also obtained from spleen precursors. BMSCs were obtained
by further culturing the adherent cells (Fig. 3A).
First, AR expression was assessed in different bone fractions from
WT mice: whole tibia, freshly-isolated BM, hematopoietic cells,
osteoclast-enriched cells (after culturing with addition of M-CSF and
RANKL) and stromal cells (Fig. 3A and B). AR mRNA expression was
the highest in stromal cells, very low in osteoclast-enriched cells
and absent in osteoclasts derived from spleen precursors (Ct values
equal to that of global ARKO).
3.3. Osteoclastogenesis and osteoclast activity in ARKO and WT mice
ARKOmice showed higher TRAP-positive osteoclast surface com-
pared to WT (Fig. 4A). In contrast, when BM cells were cultured in
vitro in the presence of RANKL and M-CSF to induce
osteoclastogenesis, the number of osteoclasts generated as well as
their activity was the same in ARKO and WT mice (Fig. 4B and C).
Next, we performed in vitro co-culture experiments of calvarial
osteoblasts from ARKO and WT mice (which provide M-CSF and
RANKL for osteoclast generationwhen treatedwith 1,25(OH)2D3), with
BM-derived cells from ARKO andWTmice. Osteoclast generation and
resorption activity were greater when both cell types in the co-
culture were from ARKOmice (Fig. 5A and B, left part). However, we
found that this effect could be attributed mainly to the BM-derived
cell fraction and not to the osteoblasts (Fig. 5A and B, right part).
3.4. Rankl, Opg, inﬂammatory cytokines and Runx2 expression in
osteoblasts and BMSCs from WT and ARKO mice
Finally, we examined the expression of key regulator genes in-
volved in osteoclastogenesis and osteoblastogenesis in osteoblasts and
BMSCs fromWT and ARKOmice. As shown in Fig. 6, RanklmRNAwas
not different in calvarial osteoblasts between ARKO and WT. As ex-
pected, Rankl expression increased in osteoblasts from both ARKO
andWT after stimulation with 1,25(OH)2D3. In BMSCs, the Rankl ex-
pression was very low and, although it was signiﬁcantly higher in
ARKO BMSCs compared toWT, 1,25(OH)2D3 treatment increased the
expression in both genotypes and abolished any difference between
them (Fig. 6). Opg expression was not different between calvarial os-
teoblasts from ARKO and WT and decreased signiﬁcantly after
1,25(OH)2D3 but only in WT osteoblasts (Fig. 6). Opg mRNA was sig-
niﬁcantly higher in ARKO compared to WT BMSCs, but only after
treatmentwith 1,25(OH)2D3 (Fig. 6). Consequently, the Rankl/Opg ratios
were similar between WT and ARKO osteoblasts, with no evidence
of increased sensitivity to 1,25(OH)2D3 stimulation (Fig. 6). The Rankl/
Opg ratio was upregulated to a greater extent by 1,25(OH)2D3
stimulation in WT compared to ARKO BMSCs (Fig. 6), which was
mainly due to lower OPG gene expression inWT stromal cells (Fig. 6).
All in all, neither osteoblasts nor BMSCs from ARKO showed an in-
creased Rankl or decreased Opg expression, which could have been
expected given the increased osteoclast surface in ARKOmice in vivo.
We also determined the transcript levels of the main
osteoclastogenic cytokines, namely TNF-α, IL-1α, IL-1β and IL-6.
Overall, the expression of the pro-inﬂammatory cytokines was in-
distinguishable between ARKO and WT BMSCs and osteoblasts,
regardless of 1,25(OH)2D3 treatment (data not shown). The effects
of 1,25(OH)2D3 stimulation on mRNA levels were restricted to IL-
1α in stromal cells, while the expression of the cytokine in
osteoblasts was below the detection limits (Fig. 6). As expected, the
expression of Runx2 (an osteoprogenitor marker) was much higher
in osteoblasts compared to BMSCs (Fig. 6). There was no differ-
ence in Runx2 expression between ARKO or WT osteoblasts,
regardless of the presence of absence of 1,25(OH)2D3. However, Runx2
expression was signiﬁcantly higher in ARKO BMSCs, both with and
without 1.25(OH)2D3 stimulation (Fig. 6).
4. Discussion
The major ﬁnding of this study is that AR expression in mouse
osteoclasts is extremely low/absent and dispensable for the androgen-
mediated inhibition of bone resorption in male mice. This is in line
with earlier studies in ORX mice with defective osteoblastogenesis,
which showed that up-regulation of osteoblastogenesis appears
Table 1
μCT and histomorphometric analysis of femur of 12- and 32-week-old ocl-ARKO and
control mice as well as bone turnover markers.
12 w 32 w
Control ocl-ARKO Control ocl-ARKO
Femur length
(mm)
15.3 ± 1.26 15.5 ± 1.6 16.1 ± 2.38 15.8 ± 1.15
BV/TV (%) 13 ± 5.38 14 ± 5.1 12 ± 6 13 ± 4.2
Tb.Th (μm) 40 ± 10.2a 38 ± 8.1b 130 ± 32.1 128 ± 36.6
Tb.N (1/mm) 3.2 ± 2.7a 3.3 ± 2.4b 2.0 ± 2.1 1.9 ± 1.5
Tb.Sp (μm) 200 ± 28.2a 203 ± 30.6b 250 ± 33.9 245 ± 38.1
Ps.Pm (mm) 5.4 ± 1.71 5.2 ± 1.02 5.3 ± 1.29 5.3 ± 1.53
Ec.Pm (mm) 3.3 ± 0.14a 3.2 ± 0.28b 3.82 ± 0.14 3.67 ± 0.16
Ct.Ar (mm2) 0.952 ± 0.07 0.924 ± 0.14 0.907 ± 0.11 0.894 ± 0.09
Me.Ar (mm2) 1.52 ± 0.16a 1.47 ± 0.14b 1.14 ± 0.17 1.15 ± 0.156
Ct.Th (μm) 187 ± 12.03 183 ± 15.72 185 ± 11.37 190 ± 12.99
Oc. S/BS (%) 3.1 ± 0.5a 3.4 ± 1.6 5.6 ± 2 4.7 ± 1.59
Osteocalcin
(ng/mL)
80 ± 21.9 81 ± 12.9 ND ND
TRACP5b (ng/mL) 11 ± 10.2 12 ± 13.2 ND ND
Bone volume/tissue volume (BV/TV); trabecular thickness (Tb.Th); trabecular number
(Tb.N); trabecular separation (Tb.Sp); periosteal perimeter (Ps.Pm); endocortical pe-
rimeter (Ec.Pm); cortical area (Ct.Ar); medullar area (Me.Ar); cortical thickness (Ct.Th);
osteoclast surface/bone surface (Oc.S/BS). Values are expressed as means (n = 4–10
mice/group) ± SD.
a p < 0.05 vs. control 32 weeks.
b p < 0.05 vs. ocl-ARKO 32 weeks.
*
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Fig. 2. Trabecular bone volume/tissue volume (BV/TV) (%) assessed by micro-CT in
the femur in control and ocl-ARKO mice after ORX and ORX+T. Values are ex-
pressed as mean (n = 10–15 mice/group) ± SEM. *p < 0.05 vs. rest of the experimental
groups.
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essential for the subsequent rise of osteoclastogenesis, arguing again
against a direct suppressive role of AR on osteoclasts or their pre-
cursors (Weinstein et al., 1997).
Nevertheless, AR and ERα in osteoclasts have been suggested to
be involved in the well-documented anti-resorptive actions of es-
trogens and androgens on bone. AR expression has been detected
by IHC and in situ-hybridization in avian and mouse osteoclasts in
vitro as well as in rat osteoclasts in vivo (Mizuno et al., 1994; Pederson
et al., 1999; Turner et al., 2008; van der Eerden et al., 2002). Fur-
thermore, androgens have been reported to inhibit osteoclast
generation and activity in vitro according to some (Chen et al., 2001;
Huber et al., 2001; Pederson et al., 1999) but not all studies (Caputo
et al., 1976; Tobias and Chambers, 1991). In vivo, ERα has been shown
to inhibit bone resorption via direct actions in osteoclasts in female
but not in male mice (Martin-Millan et al., 2010; Nakamura et al.,
2007). These results opened the possibility that the AR could have
a similar role in osteoclasts in male mice, as suggested by the work
of Nakamura et al. in 2004, in which the Cre expression was also
controlled by the cathepsin K (Ctsk) promoter (Nakamura et al.,
2004).
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Fig. 3. (A) Overview of bone fractions employed in this study. Detailed protocols are given in Section 2. (B) AR mRNA expression levels relative to hypoxanthine–guanine
phosphoribosyltransferase (HPRT) in total tibia, calvarial osteoblasts, bone marrow (BM), stromal cells, hematopoietic cells (HPC), osteoclast-enriched fraction and osteo-
clasts derived from spleen precursors. Values are the mean of three independent experiments (n = 3 mice/group in each experiment) ± SEM.
O
c.
S
/B
S
 (
%
)
0
2
4
6 *
A B C
In vivo In vitro + RANKL/M-CSF
O
st
eo
cl
as
t n
um
be
r 
/ X
20
 fi
el
d
0
2
4
6
%
 r
es
or
be
d 
su
rf
ac
e
0
4
8
12
WT ARKO WT ARKO WT ARKO
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ﬁeld and (C) % resorbed surface/total surface by osteoclasts.
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To the best of our knowledge, AR expression in murine osteo-
clasts as assessed by qPCR has only been determined in two studies
thus far (Turner et al., 2008; Ucer et al., 2015). AR mRNA levels in
the in vitro generated osteoclasts were, however, extremely low and
the possibility of contaminationwith AR from stromal cells could not
be excluded. Accordingly, in our conditions the AR expression was
also very low in osteoclast-enriched cells compared to osteoblasts
or BM cells. Moreover, here, we generated mature osteoclasts from
spleen precursors in order to circumvent the potential stromal con-
tamination in the osteoclast-enriched fraction. Interestingly, ARmRNA
expression was absent in these cultures, being the CT values equal
to that of global ARKO (background noise). Therefore, these new ﬁnd-
ings suggest that murine osteoclasts do not represent a direct cellular
target for androgenic action. Nevertheless, we tried to generate an
osteoclast-speciﬁc ARKO using Ctsk-Cre mice (Chiu et al., 2004). The
Ctsk-Cre mice have been previously used to successfully knockout
the calcitonin receptor speciﬁcally in osteoclasts (Turner et al., 2011).
In contrast to global ARKOmice (Callewaert et al., 2009; Kawano et al.,
2003) and the earlier reported abstract of osteoclast-speciﬁc ARKO
mice (Nakamura et al., 2004), our ocl-ARKOmice did not exhibit os-
teopenia nor changes in osteoclast surface and responded normally
to ORX as well as androgen replacement in vivo. However, our ﬁnd-
ings are in agreement with a recent study by Ucer et al. using an ocl-
ARKOmousemodel driven by the LysM promoter (Ucer et al., 2015).
The authors failed to demonstrate a bone phenotype in these animals
despite that in their ocl-ARKO the ARwas already deleted inmyeloid
precursors. Therefore, the study discussed earlier rules out the pos-
sibility that the osteoclast stage was a determinant factor for the
observed negative results here.
In contrast to ocl-ARKOmice, tibiae of ubiquitous ARKOmice dis-
played increased osteoclast counts Therefore, the role of the AR was
further explored using cell cultures from these animals and their
WT littermates. In accordance with earlier studies, in vitro
osteoclastogenesis as well as resorption activity was not different
in the global ARKO vs. WT in the presence of RANKL and M-CSF,
which again argues against a direct role for AR in osteoclasts as well
as in osteoclast precursor cells (Kawano et al., 2003). Thus, in the
next set of experiments, we co-cultured osteoblasts and BMSCs in
order to test if the AR might control osteoclast activity indirectly
by acting on these bone cell lineages. Also in agreement with earlier
data, both osteoclast generation and activity were suppressed in the
presence of AR in osteoblasts and BM cell co-cultures (Kawano et al.,
2003). In contrast with these earlier ﬁndings (Kawano et al., 2003)
however, co-culturing WT osteoblasts with ARKO BM cells and vice
versa showed that BM cells and not osteoblasts mediate the in-
creased osteoclast generation and activity in ARKO mice (Fig. 5).
Because the BM cell fraction consists of hematopoietic-lineage cells
(pre-osteoclasts) and BMSCs, and no direct effect via hematopoi-
etic cells could be demonstrated (Fig. 4), we hypothesize that BMSCs
are more important for the effects of AR on the regulation of bone
resorption than currently realized. Similarly, a recent study re-
ported that AR in stromal cells contributes to the effects of androgens
on muscle (Ipulan et al., 2014). However, care must be taken not
to overinterpret results from in vitro studies, and the contribution
of mesenchymal stromal cells to AR effects on bone requires con-
ﬁrmation in future conditional mouse deletion studies.
Both osteoblasts and osteoblast progenitor cells produce RANKL and
OPG which are key factors for osteoclast formation and activity. Con-
trary to earlier ﬁndings however, we found no evidence that AR
suppresses bone resorption by regulating the RANKL/OPG pathway
(Kawano et al., 2003). On the contrary, we found that Opg mRNA ex-
pression was increased in ARKO BMSCs, in line with other previous
studies (Hofbauer et al., 2002). Soluble RANKL in BM may still in-
crease following androgen deﬁciency via indirectmechanisms, such as
increased release by matrix metalloproteinases (Proell et al., 2009).
Interestingly, the expression of Runx2, which is a marker of com-
mitment to the osteoblast lineage,was also signiﬁcantly higher in ARKO
compared toWT BMSCs (Fig. 6H). Although suboptimal RUNX2 activ-
ity leads to compromised osteoblastogenesis and insuﬃcient bone
formation, supra-optimal activity also leads to an exaggerated
osteoclastogenesis andhigh-turnover osteopenia (Liu et al., 2001). There-
fore, we hypothesize that the high-turnover osteopenia in ARKOmice
might be due to unrestrained osteoblastogenesis because the AR fails
to suppress osteoblast commitment of BMSCs.
In conclusion, the presence of AR in osteoclasts is doubtful, and
does not explain the suppressive action of AR on osteoclastogenesis
and activity. Suppression of BMSC commitment to the osteoblast
lineage may represent an alternative indirect mechanism for the
antiresorptive action of AR which requires further conﬁrmation.
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